A Phase 1b, Exploratory, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SDI-118 in Elderly Male and Female Study Participants With Cognitive Decline
Latest Information Update: 25 Apr 2022
At a glance
- Drugs ABBV 552 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions
- Sponsors Syndesi Therapeutics
Most Recent Events
- 14 Apr 2022 Status changed from recruiting to discontinued since development plan changed
- 28 Jan 2022 New trial record